Business
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product
About this update from Zymeworks Inc.
[{"type":"text","content":"Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugateNext generation trispecific T cell engager platforms with integrated CD28 costimulation demonstrate durable anti-tumor activity VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024. “Our team is especially excited to participate in AACR this year to highlight some recent advancements in the development of our next generation antibody-drug conjugate and multispecific antibody therapeutics,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “Five abstracts being accepted underscores the strong progress we continue to make in advancing multiple development programs based on our proprietary engineering platforms and integrated technologies.” Presentation Details Antibody-Drug Conjugates Title: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indicationsAbstract: 1862Session Category: Experimental and Molecular TherapeuticsSession Title: Antibody-Based Technologies and New Inhibitors Title: Screening novel format antibodies to design bispecific ADCs that address target heterogeneityAbstract: 2052Session Category: Experimental and Molecular TherapeuticsSession Title: New Technologies Title: Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugatesAbstract: 3127Session Category: Experimental and Molecular TherapeuticsSession Title: Antibody-Drug Conjugates Multispecific Antibody Therapeutics Title: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancersAbstract:...